KPIs & Operating Metrics(New)
Growth Metrics

Bristol Myers Squibb (BMY) Receivables - Net (2016 - 2025)

Historic Receivables - Net for Bristol Myers Squibb (BMY) over the last 17 years, with Q4 2025 value amounting to $11.4 billion.

  • Bristol Myers Squibb's Receivables - Net rose 620.64% to $11.4 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $11.4 billion, marking a year-over-year increase of 620.64%. This contributed to the annual value of $11.4 billion for FY2025, which is 620.64% up from last year.
  • Per Bristol Myers Squibb's latest filing, its Receivables - Net stood at $11.4 billion for Q4 2025, which was up 620.64% from $11.4 billion recorded in Q3 2025.
  • In the past 5 years, Bristol Myers Squibb's Receivables - Net registered a high of $11.4 billion during Q2 2024, and its lowest value of $8.5 billion during Q1 2022.
  • Moreover, its 5-year median value for Receivables - Net was $10.2 billion (2023), whereas its average is $10.2 billion.
  • In the last 5 years, Bristol Myers Squibb's Receivables - Net crashed by 172.06% in 2022 and then surged by 1812.95% in 2023.
  • Quarter analysis of 5 years shows Bristol Myers Squibb's Receivables - Net stood at $9.4 billion in 2021, then increased by 5.52% to $9.9 billion in 2022, then grew by 10.47% to $10.9 billion in 2023, then decreased by 1.59% to $10.7 billion in 2024, then increased by 6.21% to $11.4 billion in 2025.
  • Its Receivables - Net stands at $11.4 billion for Q4 2025, versus $11.4 billion for Q3 2025 and $11.4 billion for Q2 2025.